(GMAB) Genmab A/S ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(GMAB) Genmab A/S Complete Analysis Pack
Unlock the Full Ansoff Matrix for Deeper Strategic Insight
This Genmab A/S Ansoff Matrix Analysis shows, in one clear matrix, growth options across market penetration, market development, product development, and diversification and is built for strategy, investment, or research use; the page includes a real preview/sample of the analysis so you can judge style and substance before buying—purchase the full version to get the complete ready-to-use report.
Market Penetration
DARZALEX hematology share
DARZALEX is already a core drug in hematology-oncology, with 2024 sales of $11.7 billion and approved use in multiple myeloma and AL amyloidosis. For Genmab A/S, market penetration means driving deeper use in the same specialist base and treatment pathways, not adding new buyers. More label wins strengthen brand share and repeat prescribing.
Teprotumumab thyroid eye disease
Teprotumumab supports market penetration by deepening use in thyroid eye disease, a defined specialty market. In the pivotal trial, 83% of patients met the proptosis response endpoint versus 10% on placebo, which helps drive adoption in endocrinology and ophthalmology care.
Ofatumumab CLL and MS base
Ofatumumab already serves two established pools: chronic lymphocytic leukemia and relapsing multiple sclerosis, with MS affecting about 2.9 million people worldwide and CLL one of the most common adult leukemias. The market penetration play is to keep prescribers and patients on the same product in current settings, so repeat use can deepen without new launch risk. That supports steady refill demand and lowers acquisition cost versus building a new market.
Amivantamab oncology franchise
Amivantamab broadens Genmab A/S reach inside the same oncology referral network, where NSCLC already drives the main use case and upper-GI expansion can add more high-value visits. In 2025, Rybrevant franchise demand stayed a key growth engine for Johnson & Johnson, with NSCLC being a large, biomarker-led market; the strategy is to convert more of the same lung and GI specialists, not chase new channels.
- Same doctors, more tumor types.
- NSCLC anchors the franchise.
- Upper-GI adds share potential.
- More usage per referral network.
Tisotumab vedotin gynecologic oncology base
Tisotumab vedotin already has a gynecologic oncology base in cervical cancer and is being pushed into ovarian and other solid tumors, which keeps it close to the same specialist prescribers. In market-penetration terms, the upside is deeper use inside a defined oncologist pool, not a new buyer group.
This is a practical fit for Genmab A/S because cervical, ovarian, and related gynecologic settings share referral paths, infusion sites, and toxicity-management needs. The company can build share by widening line-of-use, raising repeat use, and strengthening guideline and real-world adoption.
- Base: gynecologic oncology specialists
- Expansion: adjacent solid tumor practice
- Logic: same prescriber network
- Goal: deeper share, not new market
Genmab Grows by Deepening Share in Specialist Care
Genmab A/S market penetration is about taking more share from the same specialist base, not finding new buyers. DARZALEX led with $11.7 billion in 2024 sales, while teprotumumab posted an 83% proptosis response in trial data, supporting deeper use in existing care paths.
| Asset | Penetration signal |
|---|---|
| DARZALEX | $11.7B sales |
| Teprotumumab | 83% response |
Ofatumumab and amivantamab also fit the same play: more use in CLL, MS, NSCLC, and upper-GI care, with repeat prescribing and guideline wins driving share.
What is included in the product
Detailed Word Document
Outlines Genmab A/S’s growth options across existing and new products and markets
Editable Excel File
Provides a clear Genmab A/S Ansoff Matrix to quickly identify growth opportunities and simplify strategic planning.
Reference Sources
Consolidates primary, peer-reviewed, regulatory, and corporate sources to validate Genmab Ansoff growth paths and speed due diligence.
Market Development
DARZALEX non-MM expansion
DARZALEX's move beyond multiple myeloma into AL amyloidosis and other non-MM blood cancers is classic market development: the same brand serves new disease segments. Johnson & Johnson reported more than $11 billion in DARZALEX sales in the latest year, showing how large the expanded pool already is. That wider label lifts Genmab A/S's royalty base without needing a new drug.
Ofatumumab from CLL to MS
Ofatumumab already spans CLL and multiple sclerosis, so Genmab A/S has turned one antibody into a true new-market move. MS affects about 2.9 million people worldwide, which widens the specialist base far beyond hematology and into neurology and autoimmunity. That shift also supports broader partner-led revenue, with Novartis reporting multi-billion-franc annual Kesimpta sales in 2024.
Amivantamab NSCLC to GI cancer
Amivantamab’s move from NSCLC into advanced or metastatic gastric and esophageal cancer is a clear market development step, opening a new solid-tumor segment. Globally, gastric cancer caused about 968,000 new cases and esophageal cancer about 511,000 in 2022, so the GI opportunity is large. For Genmab A/S, this broadens the asset beyond lung oncology and deepens the addressable market.
Tisotumab vedotin beyond cervical cancer
Tisotumab vedotin (Tivdak) began in cervical cancer, where innovaTV 301 showed median overall survival of 11.5 months versus 9.5 months for chemotherapy. Genmab and Pfizer are now testing it in ovarian and other solid tumors, so this is market development for an existing asset. It expands one ADC into more oncology niches.
- Existing asset, new tumor types
- Broader solid-tumor reach
- Built on cervical-cancer data
Teprotumumab specialty eye care
Teprotumumab is already commercialized for thyroid eye disease, so this move fits Genmab A/S as a specialty non-oncology market entry into ophthalmology and endocrine care. The regimen is 8 infusions over 24 weeks, which gives Genmab a clear use case in a high-touch specialist setting.
That matters because thyroid eye disease is rare but serious, and treatment sits with ophthalmologists and endocrinologists rather than broad primary care. One clean takeaway: Genmab A/S is not just adding a drug, it is opening a new specialty channel.
- Specialty non-oncology market
- Ophthalmology and endocrine entry
- 8 infusions over 24 weeks
Genmab’s Growth Play: Expanding Proven Antibodies Into New Markets
Genmab A/S’s market development is about taking proven antibodies into new disease areas, not new science. DARZALEX now reaches beyond multiple myeloma, Kesimpta expanded into neurology, and amivantamab and Tivdak are moving into new solid-tumor settings. Teprotumumab adds a rare non-oncology entry in thyroid eye disease.
| Asset | New market | Key data |
|---|---|---|
| DARZALEX | AL amyloidosis | J&J sales above $11bn |
| Kesimpta | MS | ~2.9m people worldwide |
| Amivantamab | GI cancers | 968k gastric, 511k esophageal |
Preview Before You Purchase
Genmab A/S Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.
Product Development
Epcoritamab B-cell malignancies
Epcoritamab extends Genmab A/S into a new product lane within existing hematology-oncology markets, targeting relapsed or refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia. As a CD3xCD20 bispecific antibody, it adds another antibody-based option in B-cell cancers and fits the Product Development move in the Ansoff Matrix. In 2025, EPKINLY was already a commercial oncology asset, so this pipeline can deepen Genmab A/S’s immune-oncology reach.
GEN1047 solid tumors
GEN1047 is Genmab A/S product development in solid tumors, so it is a new offer in the company’s core oncology market. Solid tumors account for about 90% of adult cancers, which gives this pipeline asset a large target pool. It supports Genmab’s 2025/2026 push to grow inside oncology rather than move into a new field.
DuoBody-PD-L1x4-1BB solid tumors
DuoBody-PD-L1x4-1BB is Genmab A/S's solid-tumor program in immuno-oncology, using a PD-L1x4-1BB bispecific design to add a differentiated mechanism to an existing cancer market. This fits product development in the Ansoff Matrix, not new-market entry. Genmab reported 2025 revenue of DKK 29.4 billion and R&D spend of DKK 9.2 billion, showing the scale behind this bet.
DuoBody-CD40x4-1BB solid tumors
DuoBody-CD40x4-1BB is a solid-tumor program that pushes Genmab A/S beyond its current cancer assets by using the DuoBody platform to pair CD40 and 4-1BB, two immune targets, in one bispecific antibody. This supports product renewal in oncology and broadens the Company Name’s pipeline beyond its marketed revenue base.
For Genmab A/S, the strategic value is clear: more shots in solid tumors, where success can scale fast if clinical data hold. The program fits an Ansoff "product development" move because it sells new oncology products to the same core cancer market.
- Two-target design: CD40 plus 4-1BB
- Focus: solid tumors
- Role: pipeline renewal in oncology
HexaBody-CD38 and DuoHexaBody-CD37
HexaBody-CD38 and DuoHexaBody-CD37 are both hematological-malignancy programs, so they fit Genmab A/S product development: new antibody assets built on its core oncology base. This extends the blood-cancer portfolio with next-generation CD38 and CD37 biology, rather than moving into a new market.
Targets blood cancers only
Adds next-gen antibody assets
Builds on oncology know-how
Product development, not market entry
Genmab Doubles Down on Oncology Pipeline Growth
Genmab A/S uses Product Development to add new oncology assets to its core cancer markets, led by EPKINLY, GEN1047, and DuoBody bispecifics in solid tumors and blood cancers. In 2025, Genmab A/S reported revenue of DKK 29.4 billion and R&D of DKK 9.2 billion, supporting this pipeline push. The strategy deepens share in oncology, not new-market entry.
| Program | Market | Fit |
|---|---|---|
| EPKINLY | Blood cancers | New product, same market |
| GEN1047 | Solid tumors | New product, same oncology base |
| DuoBody bispecifics | Oncology | Pipeline renewal |
Diversification
PRV-015 celiac disease
PRV-015 in Phase 2 for celiac disease is a clear diversification move for Genmab A/S, pushing it from oncology into a non-oncology autoimmune area. Celiac disease affects about 1% of people worldwide, or roughly 70 million patients, but most remain undiagnosed, so the unmet need is large. This is a new product for a new disease category, which adds both growth upside and clinical risk.
Mim8 haemophilia A
mim8’s Phase 2 move into haemophilia A is a diversification play for Genmab A/S, taking it beyond its core oncology base into a rare bleeding disorder. Haemophilia A affects about 1 in 5,000 male births, so the market is smaller than cancer but can support premium pricing and long treatment cycles. Still, Phase 2 means clinical and regulatory risk remains high.
Lu AF82422 multiple system atrophy
Lu AF82422 is in Phase 2 for multiple system atrophy, a rare neurodegenerative disease with no approved disease-modifying therapy. That move takes Genmab A/S into a new market beyond oncology and hematology, broadening its R&D risk and revenue options. It also fits a diversification play by adding a high-unmet-need CNS program to a portfolio still anchored by cancer and blood disorder assets.
CureVac mRNA antibody products
Genmab’s CureVac tie-up moves it into mRNA-based antibody products, which is a clear diversification step beyond classic antibody discovery. The deal gives Genmab access to a new platform for differentiated products and expands its technology base, not just its pipeline.
Moves into new product space
Uses mRNA, not only antibodies
Broadens future growth options
Approximately 20 pre-clinical programs
Genmab A/S’s roughly 20 active pre-clinical programs widen its future entry points beyond today’s marketed portfolio. That gives the company several shots at new antibodies, targets, and indications, which lowers reliance on any one product. It also supports longer-term diversification as assets move into clinical testing.
- ~20 pre-clinical programs
- More product entry points
- Broader indication spread
Genmab Broadens Beyond Oncology With New Pipeline Bets
Genmab A/S’s diversification push is real: PRV-015, mim8, and Lu AF82422 each enter new diseases outside oncology, while the CureVac deal adds an mRNA platform. Together, these moves spread risk across autoimmune, bleeding, and CNS markets. The pipeline now also includes about 20 pre-clinical programs, widening future entry points.
| Move | Signal |
|---|---|
| PRV-015 | Celiac disease |
| mim8 | Haemophilia A |
| Lu AF82422 | Multiple system atrophy |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.